BOULDER — Array BioPharma Inc, a biopharmaceutical company based in Boulder, said Thursday it has hired a former executive at Bristol-Myers Squibb as chief financial officer.
Jason Haddock will take over for David Horin, who had been acting as Array’s interim CFO. Horin will provide consulting services to Array (Nasdaq: ARRY), which is developing drugs to treat cancer.
Haddock has more than 15 years of financial and operational experience in the biopharma industry. He held leadership positions of increasing responsibility at Bristol-Myers Squibb, a global pharmaceutical company with a strong focus on immuno-oncology therapies, in a variety of accounting, planning, commercial, analytical and business-development capacities for more than 13 years through 2015.
Haddock most recently served as CFO and chief operating officer of BERG Health, an oncology-focused research, diagnostics and development company.
“We are pleased to welcome Jason to Array’s executive team during a pivotal time for our company,” said Ron Squarer, Array’s chief executive. “He brings strong financial and operational expertise across many therapeutic areas and in commercial, medical and operational functions, and is well-versed on the nuances and challenges in the pharmaceutical landscape.”
Array is working toward commercializing two wholly owned drugs in the United States. Array is approaching several near-term milestones, including what the company expects to be positive results from a phase 3 trial and a projected regulatory filing of binimetinib in combination with encorafenib.